INZY: Beryl and David Witkin Report No Beneficial Ownership
Rhea-AI Filing Summary
Inozyme Pharma, Inc. has a Schedule 13G/A filing in which Beryl Capital entities and David A. Witkin report zero beneficial ownership of the company’s common stock, representing 0% of the class. The filers expressly disclaim beneficial ownership except for any pecuniary interest and note Beryl’s role as an investment adviser and general partner and Mr. Witkin’s role as a control person.
The filing includes certifications that any securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The submission is informational and does not report a material ownership stake.
Positive
- None.
Negative
- None.
Insights
TL;DR: Beryl and related parties disclose no economic stake in Inozyme; the filing is informational with no material ownership disclosed.
The Schedule 13G/A shows each reporting person — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin — holds 0 shares (0%) of Inozyme common stock. The filing notes Beryl acts as an investment adviser and general partner and Mr. Witkin as a control person, and includes the standard certification that holdings were not acquired to influence control. For investors, this report provides transparency but contains no material change to ownership structure or control.
TL;DR: No governance influence implied — filers disclaim beneficial ownership and report no holdings of Inozyme stock.
The submission reiterates that the reporting persons disclaim beneficial ownership and that Beryl serves in advisory and GP capacities while Mr. Witkin is identified as a control person of the adviser. An exhibit references a joint-filing agreement. Because the filing reports 0% ownership and includes certifications against acquisition to change control, there are no disclosed governance or control implications arising from this filing itself.
FAQ
Who filed the Schedule 13G/A for Inozyme (INZY)?
Does the filing indicate an intent to influence control of Inozyme (INZY)?
What roles do the filers state they hold?
Is there any reported ownership above 5% in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.